Trials / Completed
CompletedNCT02224846
A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction
Postmarketing Surveillance Study: A Randomized, Open-Label, 3-Month Interventional Study of Tadalafil Effectiveness (2.5 mg and 5 mg) and Long-Term Safety Administered Once Daily in Chinese Men With Erectile Dysfunction
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 635 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 22 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of the study drug, taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED). The study will last about up to 25 months for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tadalafil | Administered orally |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-05-01
- Completion
- 2017-05-01
- First posted
- 2014-08-25
- Last updated
- 2019-09-23
- Results posted
- 2017-10-27
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02224846. Inclusion in this directory is not an endorsement.